Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up

$
0
0
Actelion Ltd. ALIOF reported second-quarter 2016 earnings of $2.13 per American Depository Receipt (ADR), up from the year-ago figure of $1.60. Reported earnings were also above the Zacks Consensus Estimate of $1.86. Revenues were up 16.1% year over year to $607.7 million, beating the Zacks Consensus Estimate of $589 million. Quarter in Detail All growth rates mentioned below are in constant exchange rates and on a year-over-year basis. Product sales were up 15%. Sales surged 25% in the U.S. driven by the launch of Uptravi, continued momentum in Opsumit and share gains in the endothelin receptor antagonist (ERA) market....

Viewing all articles
Browse latest Browse all 480

Trending Articles